The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Telehealth consultations and recruitment trends in clinical trials: A retrospective analysis at investigational cancer therapeutics, a dedicated phase I department at The University of Texas MD Anderson Cancer Center.
 
Carlos Torrado
No Relationships to Disclose
 
Amanda Brink
No Relationships to Disclose
 
Mohamed Alaa Gouda
No Relationships to Disclose
 
Lei Kang
No Relationships to Disclose
 
Jessica Osburn
No Relationships to Disclose
 
Clover J Patterson
No Relationships to Disclose
 
Sheena Charles
No Relationships to Disclose
 
Anna Poullard
No Relationships to Disclose
 
Gabriele E Urschel
No Relationships to Disclose
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics; Fate Therapeutics; Mersana; PMV Pharma; Summit Therapeutics
Speakers' Bureau - PMV Pharma
Research Funding - A2A Pharmaceuticals (Inst); Aileron Therapeutics (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Compugen (Inst); Dragonfly Therapeutics (Inst); Genentech (Inst); Immunocore (Inst); Immunomedics/Gilead (Inst); Mereo BioPharma 5 (Inst); Mersana (Inst); PMV Pharma (Inst); Poseida (Inst); Rain Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Soto (Inst); Triumvira Immunologics, Inc (Inst); Volastra Therapeutics (Inst)
Travel, Accommodations, Expenses - Rain Oncology; Triumvira Immunologics, Inc
 
Daniel D. Karp
No Relationships to Disclose
 
Aung Naing
Employment - MD Anderson Cancer Center
Honoraria - AKH Inc.; American Society of Clinical Oncology; CME Outfitters; ESMO; Korean Society of Medical Oncology (KSMO); Lynx Group; Scripps Hospital; Society for Immunotherapy of Cancer
Consulting or Advisory Role - Abbvie; CytomX Therapeutics; Deka Biosciences; Genome & Company; Horizon Therapeutics (I); Immune-Onc Therapeutics; Lynx Health; Merk Sharp & Dohme Corp; NGM Biopharmaceuticals; Nouscom; OncoNano Inc; OncoSec; Pharming NV (I); PsiOxus Therapeutics; PsiOxus Therapeutics; SERVIER; STCube Pharmaceuticals Inc.; Takeda (I)
Research Funding - Amplimmune; Arcus Biosciences; ARMO BioSciences; Atterocor; Baxalta (I); BioNTech SE; Bristol-Myers Squibb; Calithera Biosciences; Chao Physician-Scientist Awards (I); CytomX Therapeutics; EMD Serono; Healios; Immune Deficiency Foundation (I); ImmuneOncia; Incyte; Jeffrey Modell Foundation (I); Karyopharm Therapeutics; Kymab; Lilly; MedImmune; Merck; Monopteros Therapeutics; NCI; NeoImmuneTech; Neon Therapeutics; Novartis; Pfizer; PsiOxus Therapeutics; Regeneron; Seven and Eight Biopharmaceuticals; Sotio; Surface Oncology; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences; NeoImmuneTech; NGM Biopharmaceuticals
 
Sarina A. Piha-Paul
Consulting or Advisory Role - CRC Oncology
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); Curis (Inst); Cyclacel (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Epigenetix (Inst); F-Star Beta Limited (Inst); F-Star Therapeutics, Ltd. (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Hengrui Pharmaceutical (Inst); HiberCell (Inst); Immunomedics (Inst); Incyte (Inst); Jacobio (Inst); Jiangsu Simcere Pharmaceutical Co. Ltd. (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); Nectin Therapeutics (Inst); NIH/NCI (Inst); Novartis (Inst); Nurix (Inst); OncoNano Inc (Inst); Pfizer (Inst); Phanes Therapeutics (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Purinomia (Inst); RAPT Therapeutics (Inst); Replimune (Inst); Roche/Blueprint (Inst); Seagen (Inst); Shasqi Inc. (Inst); Shasqi Inc. (Inst); Silverback Therapeutics (Inst); Synlogic (Inst); Taiho Oncology (Inst); Tallac Therapeutics, Inc. (Inst); Tesaro (Inst); Theradex (Inst); Theradex (Inst); Toragen Therapeutics, Inc. (Inst); TransThera Biosciences (Inst); Xencor (Inst); ZielBio (Inst)
 
Paula R Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences; SABCS
Consulting or Advisory Role - Abbvie; Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Carisma Therapeutics (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Orum Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); SEAGEN (Inst); SEAGEN (Inst); SEAGEN (Inst)
Patents, Royalties, Other Intellectual Property - Patent application; United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
(OPTIONAL) Uncompensated Relationships - Jazz Pharmaceuticals; Pfizer; SEAGEN
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Alynlam Pharmaceuticals; Avoro Capital Advisors; Boxer Capital; Chinese University of Hong Kong; Clarion Healthcare; Columbus Venture Partners; Cullgen; Debiopharm Group; Ellipses Pharma; Envision Pharma Group; Incyte; iOnctura; Macrogenics; Merus; Monte Rosa Therapeutics; Oncology One; Pfizer; Sardona Therapeutics; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO; Loxo
Other Relationship - Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Avstera; BioEclipse Therapeutics; BrYet; Diaccurate; Macrogenics; Nex-I; Vincerx Pharma
Research Funding - Agenus (Inst); BrYet; IMMATICS (Inst); Novocure (Inst); OBI Pharma (Inst); Orionis (Inst); Parker Institute for Cancer Immunotherapy (Inst); Tachyon (Inst); Tempus (Inst); Tempus (Inst); Tvardi Therapeutics (Inst)
 
Timothy A. Yap
Employment - MD Anderson Cancer Center
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - 858 Therapeutics; Abbvie; Acrivon Therapeutics; Adagene; Aduro Biotech; Almac Group; Amphista Therapeutics; Artios; Astex Pharmaceuticals; AstraZeneca; Athenahealth; Atrin Pharmaceuticals; Avenzo; Avoro Capital Advisors; Axiom Biotechnologies; Baptist Health; Bayer; BeiGene; BioCity Pharma; Blueprint Medicines; Boxer; Bristol-Myers Squibb; C4 Therapeutics; Calithera Biosciences; Cancer Research UK; Carrick Therapeutics; Circle Pharma; Clovis Oncology; Cybrexa Therapeutics; Daiichi Sankyo; Dark Blue Therapeutics; Diffusion Pharmaceuticals; Duke Street Bio; EcoR1 Capital; Ellipses Pharma; EMD Serono; Entos; F-Star; Genesis Therapeutics; Genmab; Gerson Lehrman Group; GlaxoSmithKline; Glenmark; Globe Life Science; Guidepoint Global; Gustave Roussy Cancer Center; I-Mab; IDEAYA Biosciences; Idience; Ignyta; ImmuneSensor Therapeutics; IMPAC Medical Systems; Intellisphere; Janssen; Kyn therapeutics; MEI Pharma; Merck; Mereo BioPharma; Merit, Inc.; Monte Rosa Therapeutics; Natera; Nested Therapeutics; Nexys Therapeutics; Nimbus Therapeutics; Novocure; Odyssey Therapeutics; OncoSec; Ono Pharmaceutical; Onxeo; Oregon Health & Science University (OHSU); PanAngium Therapeutics; Pegascy; PER; Pfizer; Piper Sandler; Pliant; ProLynx; Radiopharma Theranostics; Repare Therapeutics; resTORbio; Roche; Ryvu Therapeutics; SAKK; Sanofi; Schrodinger; SERVIER; Synnovation; Synthis Therapeutics; Tango Therapeutics; TCG Crossover; TD2; Terns Pharmaceuticals; Terremoto Biosciences; Tessellate Bio; Theragnostics; Thryv Therapeutics; Tolremo; Tome; Trevarx Biomedical; Varian Medical Systems; Veeva; Versant Health; Vibliome Therapeutics; Voronoi Health Analytics; Xinthera; Zai Lab; ZielBio
Research Funding - Acrivon Therapeutics (Inst); Artios (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BioNTech (Inst); Blueprint Medicines (Inst); BMS (Inst); Boundless Bio; Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Haihe Biopharma (Inst); IDEAYA Biosciences; ImmuneSensor Therapeutics (Inst); InSilico Medicine; Ionis Pharmaceuticals (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); KSQ Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tango Therapeutics; Tesaro (Inst); Vivace Therapeutics (Inst); Zenith Epigenetics (Inst)
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Telperian
Consulting or Advisory Role - 28Bio; Acuta; Adaptimmune; Alkermes; Alphasights; Amgen; AUM Biosciences; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; Bridgebio; COG; Cor2Ed; Cowen; EcoR1 Capital; Exelixis; Experimental Drug Development Centre (EDDC)/A*STAR; Genentech; Gennao Bio; Gerson Lehrman Group; Gilead Sciences; GroupH; Guidepoint Global; HCW Precision; Immunogen; Incyte; Infinity Pharmaceuticals; Inhibrix Inc; Janssen; Jounce Therapeutics; Liberum; MedaCorp; Medscape; Novartis; Numab; Oncologia Brasil; Pfizer; Pharma Intelligence; Precision Oncology Experimental Therapeutics; Prime Oncology; RAIN; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; Turning Point Therapeutics; WebMD; YingLing Pharma; ZIOPHARM Oncology
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); F. Hoffmann LaRoche (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Pyramid Biosciences (Inst); Seagen (Inst); Takeda (Inst); TCR2 Therapeutics (Inst); Teckro (Inst); Turning Point Therapeutics (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; CLCC; Genmab; Society for Immunotherapy of Cancer; Telperian
 
Funda Meric-Bernstam
Employment - MD Anderson Cancer Center
Honoraria - Dava Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca; Black Diamond Therapeutics; Calibr; Daiichi Sankyo/Astra Zeneca; EcoR1 Capital; Eisai; Exelixis; GT Aperion; Incyte; Infinity Pharmaceuticals; Karyopharm Therapeutics; LegoChem Biosciences; Lengo Therapeutics; Menarini Group; OnCusp Therapeutics; Protai; Seagen; Tallac Therapeutics; Theratechnologies; Zentalis; Zymeworks
Research Funding - Abbvie (Inst); Aileron Therapeutics (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); eFFECTOR Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Jazz Pharmaceuticals (Inst); Klus Pharma (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARTIDIS; Cholangiocarcinoma Foundation; Dava Oncology; ESMO; European Organisation for Research and Treatment of Cancer (EORTC)
 
Siqing Fu
Research Funding - Abbisko (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); CUE Biopharma (Inst); Exelis (Inst); Exelis (Inst); Greenfire Bio (Inst); Hookipa Pharma (Inst); IMV (Inst); Innovent Biologics (Inst); K-Group Beta (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); MediLink Therapeutics (Inst); Millennium (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NextCure (Inst); NIH/NCI (Inst); Ningbo NewBay Medical Technology (Inst); Novartis (Inst); NovoCure (Inst); Nykode Therapeutics (Inst); Parexel International, LLC (Inst); Pionyr (Inst); PureTech (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); SQZ Biotech (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Taiho Oncology (Inst); Treadwell Therapeutics (Inst); Turnstone Bio (Inst); Tyligand Bioscience (Inst); Virogin Biotech (Inst)